Abstract
Even though protein tyrosine phosphatase has been identified as a validated therapeutic target over a decade for type II diabetes and obesity, developing a selective inhibitor to protein tyrosine phosphatase 1B (PTP1B) over other cellular PTPases has been a complicated task owing to the highly conserved and polar nature of the PTP1B catalytic site. Virtual screening study of in-house chemical depository resulted in the prioritization of few low molecular weight compounds as PTP1B inhibitors. The in-vitro pNPP assays were carried out on prioritized compounds in both PTP1B and T-cell protein tyrosine phosphatase (TCPTP). From this we identified four low molecular weight compounds as PTP1B inhibitors, of which the compound AU-2439 has shown 5 fold selectivity towards PTP1B over highly homologous TCPTP. In this short communication selectivity of AU-2439 is explained based on interaction with critical active site residues in both proteins using docking models.
Keywords: PTP1B, TCPTP, p-Nitro phenyl phosphate, Type II diabetes, Obesity.
Mini-Reviews in Medicinal Chemistry
Title:Diphenylether Derivative as Selective Inhibitor of Protein Tyrosine Phosphatase 1B (PTP1B) Over T-cell Protein Tyrosine Phosphatase (TCPTP) Identified through Virtual Screening
Volume: 13 Issue: 11
Author(s): M. V.V.V. Sekhar Reddy, Chakshusmathi Ghadiyaram, Sunil Kumar Panigrahi, Subramanya Hosahalli and Lakshmi Narasu Mangamoori
Affiliation:
Keywords: PTP1B, TCPTP, p-Nitro phenyl phosphate, Type II diabetes, Obesity.
Abstract: Even though protein tyrosine phosphatase has been identified as a validated therapeutic target over a decade for type II diabetes and obesity, developing a selective inhibitor to protein tyrosine phosphatase 1B (PTP1B) over other cellular PTPases has been a complicated task owing to the highly conserved and polar nature of the PTP1B catalytic site. Virtual screening study of in-house chemical depository resulted in the prioritization of few low molecular weight compounds as PTP1B inhibitors. The in-vitro pNPP assays were carried out on prioritized compounds in both PTP1B and T-cell protein tyrosine phosphatase (TCPTP). From this we identified four low molecular weight compounds as PTP1B inhibitors, of which the compound AU-2439 has shown 5 fold selectivity towards PTP1B over highly homologous TCPTP. In this short communication selectivity of AU-2439 is explained based on interaction with critical active site residues in both proteins using docking models.
Export Options
About this article
Cite this article as:
Reddy V.V.V. Sekhar M., Ghadiyaram Chakshusmathi, Panigrahi Kumar Sunil, Hosahalli Subramanya and Mangamoori Narasu Lakshmi, Diphenylether Derivative as Selective Inhibitor of Protein Tyrosine Phosphatase 1B (PTP1B) Over T-cell Protein Tyrosine Phosphatase (TCPTP) Identified through Virtual Screening, Mini-Reviews in Medicinal Chemistry 2013; 13 (11) . https://dx.doi.org/10.2174/1389557511313110006
DOI https://dx.doi.org/10.2174/1389557511313110006 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chromatographic Fingerprinting and Metabolomics for Quality Control of TCM
Combinatorial Chemistry & High Throughput Screening The Pathogenesis of Susceptibility to Acute Kidney Injury in the Elderly
Current Aging Science Diabetes NEP-Like Endopeptidases and Alzheimers Disease
Current Alzheimer Research Acknowledgements to Reviewers:
Endocrine, Metabolic & Immune Disorders - Drug Targets Pathophysiological Implications of Dipeptidyl Peptidases
Current Protein & Peptide Science Fitness or Fatness - the Debate Continues for the Role of Leptin in Obesity-Associated Heart Dysfunction
Current Diabetes Reviews Diet Bioactive Compounds: Implications for Oxidative Stress and Inflammation in the Vascular System
Endocrine, Metabolic & Immune Disorders - Drug Targets Cell Wall Associated Factors of Mycobacterium tuberculosis as Major Virulence Determinants: Current Perspectives in Drugs Discovery and Design
Current Drug Targets A form of Autoimmune Diabetes in Adults Named LADA – An Update on Essential Features and Controversies
Current Diabetes Reviews Hypertension in Peripheral Arterial Disease
Current Pharmaceutical Design Critical Aspects to be Considered Prior to Large-Scale Production of Peptides
Current Protein & Peptide Science Molecularly Targeted Therapy in Breast Cancer: The New Generation
Recent Patents on Anti-Cancer Drug Discovery Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases
Current Pharmaceutical Design Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeted Blood-to-Brain Drug Delivery – 10 Key Development Criteria
Current Pharmaceutical Biotechnology A Dig Deep to Scout the Pharmacological and Clinical Facet of Garlic (<i>Allium sativum</i>)
Current Traditional Medicine Eating Disorders in Athletes: From Risk Management to Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Interactions of VIP, Secretin and PACAP1-38 with Phospholipids: A Biological Paradox Revisited
Current Pharmaceutical Design Biomedical Applications of Natural Polymers for Drug Delivery
Current Organic Chemistry